Clinical Trial

TULIP ReTrain Study

Study acronym: TULIP ReTrain
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two different ultrasound contrast agents: Sonovue and Optison. Data will be collected using a commercial version of the LOGIQ E10 ultrasound machine, with full histopathological correlation in patients undergoing radical prostatectomy.
Trial Details
NCT Number NCT06974539
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Angiogenesis Analytics
Conditions Prostate Cancer
Enrollment 212 participants
Start Date 2025-07
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-16